Goldman Sachs downgraded NASDAQ:MLTX to "Sell" with a price target of $10, indicating a potential decrease of approximately -42.56%.MoonLake Immunotherapeutics received positive feedback from the FDA for its lead product, Sonelokimab (SLK), for treating Hidradenitis Suppurativa (HS).The company plans to submit a Biologic License Application (BLA) for SLK in HS in the second half of 2026, potentially expediting the approval process.MoonLake Immunotherapeutics, trading on NASDAQ under the symbol MLTX, is a cl ...